NL-OMON34217尚未招募不适用
Regulation of LPL in patients with the metabolic syndrome - LPL and MetS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patient with metabolic syndrome will have to meet at least three of the following criteria (HTG will be a mandatory criteria).
- •o Central obesity; WC > 94 cm in male and > 80 cm in female
- •o Elevated plasma triglycerides 2.0-6.0 mmol/L
- •o Fasting plasma glucose (FPG) < 5.6 mmol/L
排除标准
- •* BMI >32
- •* Cardiovascular disease
- •* Current use of the following medications: Heparin, or other blood diluting medication
- •* Hepatic dysfunction
- •* End stage renal disease
- •* History of bleeding or recent surgical intervention
研究者
相似试验
进行中（未招募）
1 期
Safety and tolerability of Trimetazidine in amyotrophic lateral sclerosis (ALS)Patients suffering from amyotrophic lateral sclerosis (ALS)EUCTR2020-005018-17-NLThe University of Queensland36
已完成
2 期
Targeting metabolic flexibility in ALS (MetFlex); safety and tolerability of trimetazidine for the treatment of ALS;An investigator initiated and conducted, multicentre, international, open-label Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND)amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)10029317NL-OMON52162niversity of Queensland10
尚未招募
1 期
Safety and tolerability of Trimetazidine in amyotrophic lateral sclerosis (ALS)Amyotrophic Lateral SclerosisNeurological - Neurodegenerative diseasesACTRN12620000945921The University of Queensland36
撤回
3 期
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular DiseaseCardiovascular DiseasesType 2 DiabetesNCT04057261RWTH Aachen University
已完成
4 期
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by GlucagonDiabetesNCT01155206University Health Network, Toronto9